Novo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024. In the quarter to June 2026, revenue grew 4.47%, EPS fell 18.7%, free cash flow grew 71.6% and total debt rose 44.4%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for five.
Follow NVO
Alert me
Novo Nordisk A/S (NVO) P/E ratio
As of 30 October 2026, Novo Nordisk A/S (NVO) trades at a P/E ratio of 9.8×. Over the past ten years it has ranged from 8.6× (April 2026) to 50.7× (June 2024); the current reading is higher than 2% of that period. That is below the Drug Manufacturers General industry median of 27.6× and below the Healthcare sector median of 25.8×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 14.7× | (43.92%) |
| FY2024 | 26.1× | (30.74%) |
| FY2023 | 37.7× | (4.36%) |
| FY2022 | 39.5× | 16.65% |
| FY2021 | 33.8× | 33.20% |
| FY2020 | 25.4× | 7.97% |
| FY2019 | 23.5× | 29.18% |
| FY2018 | 18.2× | (21.64%) |
| FY2017 | 23.2× | 44.31% |
| FY2016 | 16.1× | (44.26%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 11.7× | 35.87% |
| Mar 2026 | 8.6× | (41.17%) |
| Dec 2025 | 14.7× | (9.10%) |
| Sep 2025 | 16.1× | (14.93%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GILD Gilead Sciences, Inc. compare | n/m |
| NVO Novo Nordisk A/S | 9.8× |
| BMY Bristol Myers Squibb Company compare | 13.8× |
| GSK GSK PLC Sponsored ADR compare | 15.4× |
| SNY Sanofi compare | 23.3× |
| NVS Novartis AG compare | 24.1× |
| AZN AstraZeneca PLC compare | 27.6× |
| AMGN Amgen Inc. compare | 28.7× |
| PFE Pfizer Inc. compare | 40.1× |
| Drug Manufacturers General industry median | 27.6× |
| Healthcare sector median | 25.8× |
| Market median | 18.6× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)